19th Ave New York, NY 95822, USA
Join Now

Welcome Letter

Dear Friends,

We greatly look forward to welcoming you on behalf of the Irish Society for Immunology (ISI) and the European Federation of Immunological Societies (EFIS) to the 7th European Congress of Immunology (ECI) in Dublin from September 1st-4th 2024.
Our theme is ‘Conquering challenges with Immunology’ and as we are finding in the context of COVID19, Immunology has a unique and transformative ability to address global public health problems.
Ireland is known for its hospitality, and we can’t wait to extend a ‘céad míle fáilte’ to the European and global immunology community for a long overdue reunion.
We will be in touch over the coming year with details on the meeting, social activities and attractions in Dublin and throughout Ireland.

Prof Ed Lavelle, ECI2024 Congress President

Dear Friends and Colleagues,

As President of the European Federation of Immunological Societies (EFIS), it is my pleasure to extend this invitation to you to join us in Dublin in September 2024 at the Seventh European Congress of Immunology (ECI 2024).
Together with our local hosts, the Irish Society for Immunology, we are working to ensure a stimulating three and one-half days to explore the most recent advances in the fields of innate and adaptive immunity, diseases of the immune system and immune interventions. And whether you have a broad-ranging interest in the multiple facets of modern immunological research, or your focus lies in a particular niche, you will surely come away from ECI 2024 satisfied by the fine balance between basic and applied/translational research contributions that the organisers intend to assemble.
ECI 2024 will also continue the tradition that is central to EFIS’ mission, namely, to foster the participation and recognition of Europe’s next generation of immunologists at major immunology-themed meetings. And at ECI 2024 early-career scientists will certainly have the chance to take centre-stage on numerous occasions. To stimulate the participation of as many junior investigators as possible, EFIS will be offering no fewer than 250 generous travel grants!
ECI 2024 is beginning to take shape and is committed to respecting its predecessors as “the” showcase for the talents of the European immunology community. I warmly encourage you to mark your calendars and to join us in Dublin to help us conquer challenges with immunology and to make ECI 2024 a resounding and rewarding success.

Sincerely,

Federica Sallusto
President, EFIS

Our website uses cookies from third party services to improve your browsing experience. Read more about this and how you can control cookies by clicking "Privacy Preferences".
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required
Google Fonts
This site uses so-called web fonts provided by Google for the uniform font representation.
Privacy Policy Cookies Policy

eLife transforms research communication to create a future where a global community of researchers produces open and trusted results. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared.
We aim to review significant immunology research spanning allergy, immunity and immunoregulation, inflammation and T-cell receptor signalling. To read the latest Immunology and Inflammation research reviewed by eLife, visit our website.

No matter where you are in your drug development journey, Charles River can provide you with a wide range of products, models, services, and guidance that are tailored to your specific needs. Our biologic and manufacturing services help you navigate seamlessly throughout the drug development cycle with a wide variety of comprehensive CGMP testing and manufacturing solutions including monoclonal antibodies/recombinant proteins, viral vectors, vaccines, and cell therapies. With over 40,000 tests run annually at our global biologics testing facilities and 200+ products supported; you can count on our expertise to ensure your therapy is safe, effective, and able to pass regulatory scrutiny.

Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers include university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality.